Literature DB >> 9193876

Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.

O V Olesen1, K Linnet.   

Abstract

The metabolism of nortriptyline was studied in vitro using cDNA-expressed human cytochrome P450 isozymes 1A2, 3A4, 2C19, and 2D6, CYP2D6 was the sole isozyme mediating hydroxylation of nortriptyline, the quantitatively most important metabolic pathway, and only (E)-10-OH-nortriptyline was formed. CYP2D6, 2C19, and 1A2, mentioned in decreasing order of significance, mediated the demethylation reaction of nortriptyline, whereas 3A4 did not participate in the metabolism of nortriptyline. Concerning the quantitative relations, CYP2D6 exhibited a high affinity with respect to hydroxylation and demethylation (K(m) 0.48-0.74 mumol/l), a high hydroxylation capacity (Vmax 130 mol/hr/mol CYP) and a somewhat lower demethylation capacity (Vmax 19 mol/ hr/mol CYP). The affinities of 1A2 and 2C19 were 100-fold lower (K(m) 54-118 mumol/l). The capacity of 1A2 was low (Vmax 6.8 mol/hr/ mol CYP), whereas 2C19 had the highest demethylation capacity (Vmax 93 mol/hr/mol CYP). Taking into account the relative amounts of CYP isozymes present in the liver, about 90% of the metabolism was estimated to depend on CYP2D6, with CYP2C19 and 1A2 mediating the remaining 10%. In subjects lacking the 2D6 isozyme, CYP2C19 and 1A2 are expected to be of major importance for elimination of nortriptyline.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193876

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.

Authors:  M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

Review 2.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

3.  Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.

Authors:  Jennifer Cohen Smith; Steven C Curry
Journal:  J Med Toxicol       Date:  2011-09

4.  IDSite: An accurate approach to predict P450-mediated drug metabolism.

Authors:  Jianing Li; Severin T Schneebeli; Joseph Bylund; Ramy Farid; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2011-11-08       Impact factor: 6.006

Review 5.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 6.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

7.  Quantitative pharmacogenetics of nortriptyline: a novel approach.

Authors:  E E Kvist; A Al-Shurbaji; M L Dahl; C Nordin; G Alván; L Ståhle
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.

Authors:  Detlef Thieme; Burkhard Rolf; Hans Sachs; Dagmar Schmid
Journal:  Int J Legal Med       Date:  2007-11-09       Impact factor: 2.686

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.